Abstract
Mannose-binding lectin (or mannan-binding lectin, MBL) may have an influence on susceptibility to infection in patients given chemotherapy to induce remission or as conditioning before stem cell transplantation. The most surprising finding reported from an inconsistent literature was the observation that mbl-2 gene mutations in donors could influence the risk of serious infections in recipients of allogeneic stem cell transplants. This could be explained if leukocytes in the stem cell preparations (or their derivatives) were able to synthesize and secrete MBL, but the available evidence seems to exclude that possibility. An alternative mechanism could involve MBL binding to autologous cells and inducing immunological maturation of those cells. MBL can certainly bind to various cell types via surface glycoconjugates and the possible significance of this for MBL replacement therapy will be discussed.
Keywords: Mannan-binding lectin, mannose-binding lectin, stem cell transplantation
Current Stem Cell Research & Therapy
Title: Stem Cell Transplantation and MBL Replacement Therapy
Volume: 3 Issue: 2
Author(s): David C. Kilpatrick
Affiliation:
Keywords: Mannan-binding lectin, mannose-binding lectin, stem cell transplantation
Abstract: Mannose-binding lectin (or mannan-binding lectin, MBL) may have an influence on susceptibility to infection in patients given chemotherapy to induce remission or as conditioning before stem cell transplantation. The most surprising finding reported from an inconsistent literature was the observation that mbl-2 gene mutations in donors could influence the risk of serious infections in recipients of allogeneic stem cell transplants. This could be explained if leukocytes in the stem cell preparations (or their derivatives) were able to synthesize and secrete MBL, but the available evidence seems to exclude that possibility. An alternative mechanism could involve MBL binding to autologous cells and inducing immunological maturation of those cells. MBL can certainly bind to various cell types via surface glycoconjugates and the possible significance of this for MBL replacement therapy will be discussed.
Export Options
About this article
Cite this article as:
Kilpatrick C. David, Stem Cell Transplantation and MBL Replacement Therapy, Current Stem Cell Research & Therapy 2008; 3 (2) . https://dx.doi.org/10.2174/157488808784223069
DOI https://dx.doi.org/10.2174/157488808784223069 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery HSP60 as a Drug Target
Current Pharmaceutical Design Neuronal Generation from Somatic Stem Cells: Current Knowledge and Perspectives on the Treatment of Acquired and Degenerative Central Nervous System Disorders
Current Gene Therapy Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Chemical and Potential Biological Perspectives of Genus Sarcococca (Buxaceae)
The Natural Products Journal Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Current Drug Targets Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course
Current Cancer Therapy Reviews Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies Inhibitors of ABL and the ABL-T315I Mutation
Current Topics in Medicinal Chemistry Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials